T1	Participants 177 229	patients with unresectable pancreatic adenocarcinoma
T3	Participants 1063 1088	25 patients were enrolled
T2	Participants 686 876	Patients with histological/cytological proven inoperable adenocarcinoma of the head of pancreas were randomised to receive KAb 201 via either the intra-arterial or intravenous delivery route
